Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

263.04
+15.136.10%
Post-market: 263.040.00000.00%17:07 EDT
Volume:1.03M
Turnover:269.94M
Market Cap:17.41B
PE:20.30
High:268.98
Open:247.65
Low:247.65
Close:247.91
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:3.65
T/O Rate:1.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:10.43
PE(LYR):-59.54

Loading ...

H.C. Wainwright trims Ascendis target, says litigation overhang removed

TIPRANKS
·
Yesterday

Ascendis Pharma a/S : H.c. Wainwright Cuts Target Price to $344 from $345

THOMSON REUTERS
·
Yesterday

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

MT Newswires Live
·
Yesterday

Movement Alert|Ascendis Pharma A/S Rises 5.92% in Regular Trading, Global Patent Settlement Reached with BioMarin Over Yuviwel

Market Focus
·
Yesterday

Ascendis Pharma price target lowered to $330 from $333 at Jefferies

TIPRANKS
·
Yesterday

Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties

Reuters
·
Yesterday

Ascendis and Biomarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to Yuviwel® (Navepegritide)

THOMSON REUTERS
·
Yesterday

Ascendis Pharma Price Target Maintained with a $345.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

TIPRANKS
·
Yesterday

Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma

THOMSON REUTERS
·
Yesterday

BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel

MT Newswires Live
·
Yesterday

Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries

THOMSON REUTERS
·
Yesterday

HC Wainwright Initiates Coverage on Ascendis Pharma A/S With Buy Rating, $345 Price Target

MT Newswires Live
·
Aug 27

Ascendis Pharma initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Aug 27

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® CNP (Navepegritide) at Isds 2026

Reuters
·
Aug 26

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® Cnp (Navepegritide) at Isds 2026

THOMSON REUTERS
·
Aug 26

Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside

Simply Wall St.
·
Aug 25

Ascendis Pharma Director Jean-Jacques Bienaime Buys USD 492,079 of Common Shares

Reuters
·
Aug 19

Eyconis Announces Initiation of First-in-Human Clinical Trial of Eyc-0305 in Treatment-NaÏVe Wet Age-Related Macular Degeneration Patients

THOMSON REUTERS
·
Aug 18

Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next

Simply Wall St.
·
Aug 16